



**World Health
Organization**

INN Working Document 17.422 rev.
ENGLISH ONLY
20/03/2018

***Pre-stems*:
Suffixes used in the selection of INN
October 2017***

Programme on International Nonproprietary Names (INN)

Technologies Standards and Norms (TSN)

Regulation of Medicines and other health technologies (RHT)

***World Health Organization,
Geneva***

© World Health Organization (2018) -This document is not issued to the general public, and all rights are reserved by the World Health Organization (WHO). The document may not be reviewed, abstracted, quoted, reproduced or translated, in part or in whole, without the prior written permission of WHO. No part of this document may be stored in a retrieval system or transmitted in any form or by any means - electronic, mechanical or other - without the prior written permission of WHO. The views expressed in documents by named authors are solely the responsibility of those authors.

*The prestems given have been flagged because they may be selected as official stems ("The use of stems in the selection of International Nonproprietary Names for Pharmaceutical Substances", 2013, WHO/EMP /RHT/TSN/2013.1). At present, they are made available for information and potential guidance to the applicants.

stem

definition

-*suffix*

-*infix*-

In bold: new pre-stems selected during the last Consultation.

In bold and underlined: pre-stems newly selected as stems

- <i>adenant</i>	adenosine receptors antagonists
- <i>algron</i>	α_1 -adrenoreceptor agonists
- <i>ampator</i>	α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators
- <i>axomab</i>	see <i>mab</i>
- <i>becestat</i>	see <i>stat</i>
- <i>berel</i>	beta estrogen receptor agonists
- <i>bresib</i>	inhibitors of the bromodomain and extra-terminal motif (BET) family of bromodomain (BRD) proteins, antineoplastics
- <i>caftor</i>	cystic fibrosis transmembrane regulator (CFTR) protein modulators
- <i>calcet/-calcet-</i>	calcium-sensing receptors (CaSR) agonists
- <i>camra</i>	intracellular adhesion molecule (ICAM-1) derivatives
- <i>casan</i>	caspase inhibitors
- <i>caserin</i>	serotonin receptor agonists (mostly 5-HT ₂)
- <i>catib</i>	cathepsin inhibitors
- <i>cerfont</i>	corticotropin-releasing factor (CRF) receptor antagonist
- <i>closporin</i>	ciclosporin derivatives
- <i>codar</i>	see <i>dar</i>
- <i>corat</i>	glucocorticoid receptor agonists
- <i>cridar</i>	see <i>dar</i>

- <i>dacin</i>	antibiotics, DNA gyrase and topoisomerase IV inhibitors
<i>dar</i>	<i>drugs used in multidrug resistance</i>
- <i>cridar</i>	acridinecarboxamide derivatives
- <i>codar</i>	pipecolinate derivatives
- <i>spodar</i>	ciclosporin D derivatives
- <i>depsin</i>	depsipeptide derivatives
- <i>dil</i>	<i>vasodilators</i>
- <i>sudil</i>	Rho protein kinase inhibitors
- <i>domide</i>	antineoplastics, thalidomide derivatives
- <i>dustat</i>	see <i>stat</i>
- <i>ectedin</i>	ecteinascidin derivatives
- <i>espib</i>	heat shock protein (HSP) 90 inhibitors (other than <i>-mycin</i>), antineoplastics
- <i>estrant</i>	estrogen antagonists
- <i>fadine</i>	monoamine transport inhibitors
- <i>farnib</i>	farnesyl transferase inhibitors
- <i>fexor</i>	farnesoid X receptor agonists
- <i>fibatide</i>	see <i>tide</i>
- <i>fulven</i>	antineoplastic, acylfulvene derivatives
- <i>gacestat</i>	see <i>-stat</i>
- <i>ganan</i>	antimicrobial, bactericidal permeability increasing polypeptides
<u>-<i>gepant</i></u>	<u>calcitonin gene-related peptide receptor antagonists</u>
- <i>gapil</i>	neuronal apoptosis inhibitors, GAPDH
- <i>golix</i>	gonadotrophin releasing hormone (GnRH) antagonists
- <i>imepodib</i>	inosine monophosphate dehydrogenase inhibitors
- <i>inurad</i>	urate transporter inhibitors

- <i>ixafor</i>	chemokine CXCR4 antagonists
- <i>ixibat</i>	ileal bile acid transporter (IBAT) inhibitors, bile acid reabsorption inhibitors
- <i>kalner</i>	openers of calcium-activated (maxi-K) K ⁺ -channels
- <i>laner</i>	antagonists of GABA (gamma-aminobutyric acid) regulated chloride channels, antiparasitic agents
- <i>leptin(e)</i>	leptin derivatives
<i>mab</i>	<i>monoclonal antibodies</i>
under species	
- <u><i>vet</i></u> -	<u>veterinary use</u>
under targets	
- <i>ami</i> -	serum amyloid protein (SAP)/amyloidosis
- <i>gr(o)</i> -	skeletal muscle mass related growth factors and receptors
- <i>melanotide</i>	<i>see tide</i>
- <i>metinib</i>	<i>see tinib</i>
- <i>moren</i>	non-peptidic growth hormone secretagogues
- <i>nesib</i>	kinesin inhibitors
- <i>neurin</i>	neurotrophins
- <i>nexor</i>	nuclear export inhibitors
<i>nil</i>	<i>benzodiazepine receptor antagonists/agonists</i>
- <i>punil</i>	mitochondrial benzodiazepine receptor (MBR)-selective agonists, also partial or inverse (purine derivatives)
- <i>opran</i>	μ-opioid receptors antagonists
- <i>osuran</i>	urotensin receptor antagonists
- <i>otilate</i>	hepatoprotectants, di(propan-2-yl) 2-(2 <i>H</i> -1,3-dithiol-2-ylidene)propanedioate and analogues
- <i>parantag</i>	antagonists of heparin and/or low-molecular weight heparins (LMWH)
- <i>paxar</i>	protease activated receptor type 1 (PAR1) antagonists
- <i>piridine</i>	serotonin receptor antagonists
- <i>plasinin</i>	inhibitors of plasminogen activator inhibitors-type 1 (PAI-1)

- <i>plenib</i>	Spleen tyrosine kinase (Syk) inhibitors
- <i>prininim</i>	nootropic agents, purine derivatives
- <i>protafib</i>	protein tyrosine phosphatase (HPTP) inhibitors
- <i>punil</i>	see <i>nil</i>
- <i>sidenib</i>	isocitrate dehydrogenase inhibitors
- <i>spodar</i>	see <i>dar</i>
- <i>stat</i> -/ <i>-stat</i>	<i>enzymes inhibitors</i>
- <i>becestat</i>	beta secretase inhibitors
- <i>dustat</i>	hypoxia inducible factor (HIF) prolyl hydroxylase inhibitors
- <i>gacestat</i>	gamma-secretase inhibitors
- <i>stinel</i>	NMDA receptor antagonist/agonists, glycine recognition site
- <i>sudil</i>	see <i>dil</i>
- <i>sulind</i>	antineoplastics, sulindac metabolites
- <i>tegravir</i>	see <i>vir</i>
- <i>terone</i>	<i>antiandrogens</i>
- <i>teronel</i>	non-steroid antiandrogens
- <i>texafin</i>	texaphyrin derivatives
- <i>tide</i>	<i>peptides and glycopeptides</i>
- <i>fibatide</i>	platelet aggregation inhibitor (GPIIb/IIIa receptor antagonist)
- <i>melanotide</i>	melanocortin receptor antagonists

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/云报告?reportId=5_25962

